Survivin -31G>C polymorphism and gastrointestinal tract cancer risk: a meta-analysis

PLoS One. 2013;8(2):e54081. doi: 10.1371/journal.pone.0054081. Epub 2013 Feb 6.

Abstract

Background: Emerging evidence showed that common functional -31G>C polymorphism (rs9904341 G>C) in the promoter region of the survivin gene is involved in the regulation of survivin expression, thus increasing an individual's susceptibility to gastrointestinal tract (GIT) cancer; but individually published results are inconclusive. The aim of this systematic review and meta-analysis was to derive a more precise estimation of the association between survivin -31G>C polymorphism and GIT cancer risk.

Methods: A literature search of PubMed, Embase, Web of Science and CBM databases was conducted from inception through July 1st, 2012. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association.

Results: Nine case-control studies were included with a total of 2,231 GIT cancer cases and 2,287 healthy controls. The results indicated that survivin -31G>C polymorphism was associated with increased risk of GIT cancer. In the stratified analysis by cancer types, significant associations were observed between survivin -31G>C polymorphism and increased risk of colorectal and gastric cancers. However, the lack of association of survivin -31G>C polymorphism with esophageal cancer risk may be due to a lack of a sufficient number of eligible studies and the influence of different genetic and environmental factors.

Conclusion: Results from the current meta-analysis suggests that survivin -31G>C polymorphism might increase the risk of GIT cancer, especially among gastric and colorectal cancers.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Case-Control Studies
  • Gastrointestinal Neoplasms / genetics*
  • Genetic Predisposition to Disease
  • Humans
  • Inhibitor of Apoptosis Proteins / genetics*
  • Polymorphism, Genetic
  • Promoter Regions, Genetic
  • Risk
  • Risk Factors
  • Survivin

Substances

  • BIRC5 protein, human
  • Inhibitor of Apoptosis Proteins
  • Survivin

Grants and funding

This was funded by the Foundation of the Science and Technology Research Project of the Higher Education Department of Liaoning Province (No. L2010695). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.